Galderma to Present Long-Term Nemluvio Data, Global Sensitive Skin Survey at EADV 2025
KEY TAKEAWAYS
- Galderma will emphasize itch and inflammation in dermatologic disease management through the reasearch it presents at EADV 2025.
Data to be presented from the Sensitive skin now affects up to 70% of people globally, per new survey data.
Nemluvio® shows long-term (extending to 104 weeks) efficacy in PN and AD, with results extending to 104 weeks.
Galderma will present new findings on sensitive skin, as well as long-term data on nemolizumab (Nemluvio®) at the 34th European Academy of Dermatology and Venereology (EADV) Congress, to be held in Paris, September 17–20, 2025, a press statement from the manufacturer confirms.
Data from Galderma's Global Sensitive Skin Faculty (GSSF) will highlight the biological effects of modern lifestyles on sensitive skin, including new findings from a real-world study conducted in China. This first-of-its-kind analysis will be presented by Prof. Adam Friedman (The George Washington University), Dr. Aaron Farberg (Baylor University Medical Center), and Prof. Martina Kerscher (University of Hamburg) during an industry hub session on September 19.
Results from the largest global survey to date on sensitive skin (including data from more than 17,000 participants) will be unveiled. The data show a 68% increase in sensitive skin prevalence over the past two decades, now affecting up to 70% of individuals worldwide. Related presentations will examine clinical differences between sensitive skin and rosacea, and evaluate the efficacy of a gentle hydroxy acid exfoliant in sensitive skin care.
Galderma said it will also present seven abstracts focused on its first-in-class anti–IL-31RA monoclonal antibody Nemluvio. Late-breaking data from a proteomic analysis of skin and blood samples from patients with moderate-to-severe AD will also be presented.
Additional long-term data will include results from the OLYMPIA and ARCADIA open-label extension studies showing sustained improvements in itch and skin lesions in PN and moderate-to-severe AD, with efficacy observed through 104 weeks in adults and adolescents. Nemluvio has received regulatory approval in the US, Europe, and several other countries for both PN and moderate-to-severe AD.
Galderma will also spotlight the centrality of itch in dermatologic disease burden in a separate symposium, with experts talking on the need to prioritize itch relief in PN and AD to improve quality of life.
"Alongside late-breaking proteomic and long-term data on Nemluvio in prurigo nodularis and atopic dermatitis, these efforts reflect our deep and enduring commitment to advancing science and improving dermatological care for patients around the world," said Flemming Ørnskov, MD, MPH, CEO of Galderma.
Source: Galderma press release, September 11, 2025.